Sulfinpyrazone and Abrocitinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Sulfinpyrazone
No brand names on recordAbrocitinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed two medicines that can each affect how your blood clots. Abrocitinib (Cibinqo) is used for eczema, and sulfinpyrazone can make your platelets less "sticky," which means bleeding may happen more easily. When they're taken together, especially during the first 3 months of starting abrocitinib, the bleeding risk can add up. Because of this, using them together during that early period is generally not recommended at all.
The good news is this is very manageable. Please don't stop either medicine on your own. Just reach out to your pharmacist or doctor soon so they can review your medicines and choose the safest plan for you.
Effect: Additive impairment of hemostasis, increasing bleeding risk.
Direction/mechanism: This is a pharmacodynamic (additive), not pharmacokinetic, interaction. Sulfinpyrazone has antiplatelet activity; abrocitinib (a JAK1 inhibitor) can lower platelet counts. Neither drug is a prodrug relevant here.
- Severity: Contraindicated during the first 3 months of abrocitinib therapy (antiplatelet agents other than low-dose aspirin, 81 mg/day or less).
- Onset: Unspecified.
- Evidence: Theoretical.
- Management: Avoid concurrent use during initial 3 months; if antiplatelet therapy is essential, consult prescriber. Monitor platelets and for signs of bleeding.
What happens
Increased risk of bleeding
Interaction Deep Dive
Giving abrocitinib together with antiplatelet drugs is contraindicated during the initial 3 months of therapy because of a heightened bleeding risk, with the exception of low-dose aspirin (no more than 81 mg per day)1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
What your care team may do:
- Because combining these during the first 3 months of abrocitinib is labeled as contraindicated, your prescriber may choose an alternative to one of the drugs, or adjust the timing of when you start.
- They may monitor you more closely for any signs of bleeding.
What you should do:
- Keep taking both exactly as prescribed until you've spoken with your care team, and don't stop on your own.
- Contact your pharmacist or prescriber promptly so they can review this combination and individualize the safest plan.
- Report unusual bruising, nosebleeds, blood in urine or stool, or bleeding that won't stop right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Sulfinpyrazone and Abrocitinib together?
Using sulfinpyrazone with abrocitinib during the first 3 months of abrocitinib treatment is contraindicated because both raise bleeding risk. Don't stop either drug on your own, but contact your pharmacist or doctor promptly to arrange a safer plan. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Sulfinpyrazone and Abrocitinib interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Sulfinpyrazone and Abrocitinib interaction managed?
What your care team may do: Because combining these during the first 3 months of abrocitinib is labeled as contraindicated, your prescriber may choose an alternative to one of the drugs, or adjust the timing of when you start. They may monitor you more closely for any signs of bleeding. What you should do: Keep taking both exactly as prescribed until you've spoken with your care team, and don't st… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Sulfinpyrazone or Abrocitinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CIBINQO(TM) oral tablets, abrocitinib oral tablets. Pfizer Labs (per FDA), New York, NY, 2022. DailyMed
Keep reading about Sulfinpyrazone
Keep reading about Abrocitinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist